Advanced delivery of Ciclosporin A: present state and perspective

Bibliography

• STAHELIN HF: The history of cyclosporin A (Sandimmune) revisited: another point of view. Experientia (1996) 52:5-13.
   PubMedGoogle Scholar
• WENGER RM: Total synthesis of ‘cyclosporin A’ and ‘cyclosporin H’, two fungal metabolites isolated from species Tolypocladium inflatum Gams. Helv. Chim. Acta (1984) 67:503-515.
   Google Scholar
• SCHUMACHER A, NORDHEIM A: Progress towards a molecular understanding of cyclosporin A-mediated immunosuppression. Clin. Investig. (1992) 70:773-779.
   PubMedGoogle Scholar
• TAYAR NE: Solvent dependent conformation and hydrogen-bonding capacity of cyclosporine A: evident from partition coefficients and molecular dynamics simulations. J. Med. Chem. (1993) 36:3757-3764.
   PubMed Web of Science ®Google Scholar
• READY A: Experience of cyclosporine. Transplant. Proc. (2004) 36:S135-S138.
   PubMed Web of Science ®Google Scholar
• CITTERIO F: Evolution of the therapeutic drug monitoring of cyclosporine. Transplant. Proc. (2004) 36(2 Suppl.):S420-S425.
   PubMed Web of Science ®Google Scholar
• FAULDS D: Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs (1993) 45:953-1040.
   PubMed Web of Science ®Google Scholar
• BUSAUSCHINA A: Cyclosporine nephrotoxicity. Transplant. Proc. (2004) 36:2295-2335.
   PubMed Web of Science ®Google Scholar
• PTACHCINSKI RJ, VENKATARAMANAN R, BURCKART GJ: Clinical pharmacokinetics of cyclosporine. Clin. Pharmacokinet. (1986) 11:107-132.
   PubMed Web of Science ®Google Scholar
• KAHAN BD: Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplant. Proc. (1985) 40:457-456.
   Google Scholar
• KELLY PA, WANG H, NAPOLI KL et al.: Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur. J. Drug Metab. (1999) 24:321-328.
   PubMed Web of Science ®Google Scholar
• SAEKI T, UEDA K, TANIGAWARA Y et al.: Human p-glycoprotein transports cyclosporin A and FK 506. J. Biol. Chem. (1993) 268:6077-6080.
   PubMed Web of Science ®Google Scholar
• LOWN KS, MAYO RR, LEICHTMAN AB et al.: Role of intestinal p-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. (1997) 62:1-13.
   PubMed Web of Science ®Google Scholar
• DREWE J, BEGLINGER C, KISSEL T: The absorption site of cyclosporine in the human gastrointestinal tract. Br. J. Clin. Pharmacol. (1992) 33:39-43.
   PubMed Web of Science ®Google Scholar
• JOHNSTON A, MARSDEN JT, HLA KK et al.: The effect of vehicle on oral absorption of cyclosporin. Br. J. Clin. Pharmacol. (1986) 21:P114.
   Google Scholar
• FRIMAN S, BÄCKMAN L: A new microemulsion formulation of cyclosporin. Pharmacokinetics and clinical features. Drug Dispos. (1996) 30:181-193.
   Google Scholar
• KOVARIK JM, MUELLER EA, VAN BREE JB et al.: Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. (1994) 83:444-446.
   PubMed Web of Science ®Google Scholar
• MOLPECERES J, CHACON M, GUZMAN M et al.: A polycaprolactone nanoparticle formulation of cyclosporine improves the prediction of area under the curve using a limited sampling strategy. Int. J. Pharm. (1999) 187:101-113.
   PubMed Web of Science ®Google Scholar
• DAI J, NAGAI T: pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int. J. Pharm. (2004) 280:229-240.
   PubMed Web of Science ®Google Scholar
• GREF R, QUELLEC P, SANCHEZ A et al.: Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur. J. Pharm. Biopharm. (2001) 51:111-118.
   PubMed Web of Science ®Google Scholar
• EL-SHABOURI MH: Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int. J. Pharm. (2002) 249:101-108.
   PubMedGoogle Scholar
• UBRICH N, SCHMIDT C, BODMEIER R et al.: Oral evaluation in rabbits of cyclosporin-loaded Eudraigit RS or RL nanoparticles. Int. J. Pharm. (2005) 288:169-175.
   PubMed Web of Science ®Google Scholar
• FORD J, WOOLFE J, FLORENCE AT: Nanospheres of cyclosporine A: poor oral absorption in dogs. Int. J. Pharm. (1999) 183:3-6.
   PubMed Web of Science ®Google Scholar
• LEE MK, CHOI L, KIM MH et al.: Pharmacokinetics and organ distribution of cyclosporin A incorporated in liposomes and mixed micelles. Int. J. Pharm (1999) 191:87-93.
   PubMed Web of Science ®Google Scholar
• MULLER RH, RUNGE S, RAVELLI V et al.: Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm. (2006) 317:82-89.
   PubMed Web of Science ®Google Scholar
• CAVANAK T, SUCKER H: Formulation of dosage forms. Prog. Allergy (1986) 38:65-72.
   PubMedGoogle Scholar
• BESARAB A, JARRELL BE, HIRSCH S et al.: Use of the isolated perfused kidney model to assess the acute pharmacologic effects of cyclosporine and its vehicle, Cremophor EL. Transplantation (1987) 44:195-201.
   PubMed Web of Science ®Google Scholar
• FRESE CE, LIU T, HONG K et al.: The increased efficacy and decreased nephrotoxicity of a cyclosporine liposome. Transplantation (1994) 57:928-932.
   PubMed Web of Science ®Google Scholar
• PAYNE NI, BROWNING I, HYNES CA: Characterization of proliposomes. J. Pharm. Sci. (1986) 75:330-333.
   PubMed Web of Science ®Google Scholar
• PAYNE NI, TIMMINS P, AMBROSE CV et al.: Proliposomes: a novel solution to an old problem. J. Pharm. Sci. (1986) 75:325-329.
   PubMed Web of Science ®Google Scholar
• KIM SJ, CHOI HK, SUH SP et al.: Pharmacokinetic and pharmacodynamic evalution of cyclosporin A O/W-emulsion and microsphere formulations in rabbits. Eur. J. Pharm. Sci. (2002) 15:497-502.
   PubMed Web of Science ®Google Scholar
• GUO J, WU T, PING Q et al.: Solubilization and pharmacokinetic behaviors of sodium cholate/lecithin-mixed micelles containing cyclosporine A. Drug Deliv. (2005) 12:35-39.
   PubMed Web of Science ®Google Scholar
• ALIABADI HM, MAHMUD A, SHARIFABADI AD: Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A. J. Control. Release (2005) 104:301-311.
   PubMed Web of Science ®Google Scholar
• SANCHEZ A, ALONSO MJ: Poly (D,L-lactide-co-glycolide) micro and nanospheres as a way to prolong blood/plasma levels of subcutaneously injected cyclosporine A. Eur. J. Pharm. Biopharm. (1995) 41:31-37.
   Web of Science ®Google Scholar
• MIZUSHIMA Y, IKOMA T, TANAKA J et al.: Injectable porous hydroxyapatite microparticles as a new carrier for protein and lipophilic drugs. J. Control. Release (2006) 110:260-265.
   PubMed Web of Science ®Google Scholar
• TRAN HS, MALLI D, CHRZANOWSKI FA et al.: Site-specific immunosuppression using a new formulation of topical cyclosporine A with polyethylene glycol-8 glyceryl caprylate/caprate. J. Surg. Res. (1999) 83:136-140.
   PubMed Web of Science ®Google Scholar
• BOS JD, MEINARDI MM: The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol. (2000) 9:165-169.
   PubMed Web of Science ®Google Scholar
• LIU H, LI S, WANG Y et al.: Effect of vehicles and enhancers on the topical delivery of cyclosporin A. Int. J. Pharm. (2006) 311:182-186.
   PubMed Web of Science ®Google Scholar
• LOPES LB, COLLETT JH, BENTLEY MV: Topical delivery of cyclosporin A: an in vitro study using monoolein as a penetration enhancer. Eur. J. Pharm. Biopharm. (2005) 60:25-30.
   PubMed Web of Science ®Google Scholar
• VERMA DD, FAHR A: Synergistic penetration enhancement effect of ethanol and phosphoilipids on the topical delivery of cyclosporin A. J. Control. Release (2004) 97:55-66.
   PubMed Web of Science ®Google Scholar
• LOPES LB, LOPES JL, OLIVEIRA DC et al.: Liquid crystalline phases of monoolein and water for topical delivery of cyclosporin A: characterization and study of in vitro and in vivo delivery. Eur. J. Pharm. Biopharm. (2006) 63:146-155.
   PubMed Web of Science ®Google Scholar
• LIU H, LI S, WANG Y, HAN F, DONG Y: Bicontinuous water-aot/tween85-isopropyl myristate microemulsion: a new vehicle for transdermal delivery of cyclosporin A. Drug Dev. Ind. Pharm. (2006) 32:549-557.
   PubMed Web of Science ®Google Scholar
• LIU H, WANG Y, HAN F et al.: Gelatin-stabilised microemulsion-based organogels facilitates percutaneous penetration of cyclosporin A in vitro and dermal pharmacokinetics in vivo. J. Pharm. Sci. (2007) (In Press).
   Google Scholar
• BILLICH A, VYPLEL H, GRASSBERGER M et al.: Novel cyclosporin derivatives featuring enhanced skin penetration despite increased molecular weight. Bioorg. Med. Chem. (2005) 13:3157-3167.
   PubMed Web of Science ®Google Scholar
• MCGRANE PL, WENDER PA, KHAVARI PA: Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat. Med. (2000) 6:1253-1257.
   PubMed Web of Science ®Google Scholar
• BOINPALLY RR, ZHOU, SL, DEVRAJ G et al.: Iontophoresis of lecithin vesicles of cyclosporin A. Int. J. Pharm. (2004) 274:185-190.
   PubMed Web of Science ®Google Scholar
• WANG S, KARA M, KRISHNAN TR: Transdermal delivery of cyclosporin A using electroporation. J. Control. Release (1998) 50:61-70.
   PubMed Web of Science ®Google Scholar
• LIU H, LI S, PAN W et al.: Investigation into the potential of low-frequency ultrasound facilitated topical delivery of cyclosporin A. In. J. Pharm. (2006) 326:32-38.
   Google Scholar
• NAKASHIMA M, ZHAO MF, OHYA H et al.: Evaluation of in-vivo transdermal absorption of cyclosporin with absoption enhancer using intradermal microdialysis in rats. J. Pharm. Pharmacol. (1996) 48:1143-1146.
   PubMed Web of Science ®Google Scholar
• CORCORAN TE: Inhaled delivery of aerosolized cyclosporine. Adv. Drug. Deliv. Res. (2006) 58:1119-1127.
   PubMed Web of Science ®Google Scholar
• DOWLING RD, ZENATI M, BURCKART GJ et al.: Aerosolized cyclosporine as single-agent immunotherapy in canine lung allografts. Surgery (1990) 108:198-204.
   PubMed Web of Science ®Google Scholar
• MUGGENBURG BA, HOOVER MD, GRIFFITH BP et al.: Administration of cyclosporine by inhalation: a feasibility study in beagle dogs. J. Aerosol Med. (1990) 3:1-13.
   Google Scholar
• BLOT F, TAVAKOLI R, SELLAM S et al.: Nebulized cyclosporine for prevention of acute pulmonary allograft rejection in the rat: pharmacokinetic and histologic study. J. Heart Lung Transplant. (1995) 14:1162-1172.
   PubMed Web of Science ®Google Scholar
• KEENAN RJ, DUNCAN AJ, YOUSEM SA et al.: Improved immunosuppression with aerosolized cyclosporine in experimental pulmonary transplantation. Transplantation (1992) 53:20-25.
   PubMed Web of Science ®Google Scholar
• IACONO AT, KEENAN RJ, DUNCAN SR et al.: Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am. J. Respir. Crit. Care Med. (1996) 153:1451-1455.
   PubMed Web of Science ®Google Scholar
• BURKART GJ, SMALDONE GC, ELDON in lung transplant patients. Pharm. Res. (2003) 20:252-256.
   PubMed Web of Science ®Google Scholar
• CORCORAN TE, SMALDONE GC, DAUBER JH et al.: Preservation of post-transplant lung function with aerosol cyclosporin. Eur. Respir. J. (2004) 23:378-383.
   PubMed Web of Science ®Google Scholar
• LETSOU GV, SAFI HJ, REARDON MJ et al.: Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Ann. Thorac. Surg. (1999) 68:2044-2048.
   PubMed Web of Science ®Google Scholar
• GILBERT BE, KNIGHT C, ALVAREZ FG et al.: Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol. Am. J. Respir. Crit. Care Med. (1997) 156:1789-1793.
   PubMed Web of Science ®Google Scholar
• KOSHKINA NV, GOLUNSKI E, ROBERTS LE et al.: Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J. Aerosol Med. (2004) 17:7-14.
   PubMedGoogle Scholar
• MATILAINEN L, JÄRVINEN K, TOROPAINEN T et al.: In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A. Int. J. Pharm. (2006) 318:41-48.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, PALESTINE AG, CHAN CC et al.: Doule-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am. J. Ophthalmol. (1991) 112:138-146.
   PubMed Web of Science ®Google Scholar
• MASUDA K, NAKAJIMA A, URAYAMA A et al.: Double-masked trial of cyclosporin in Behcet's disease. Lancet (1989) 1:1093-1093.
   PubMed Web of Science ®Google Scholar
• OLIVERO DK, DAVIDSON MG, ENGLISH RV et al.: Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. J. Am. Vet. Med. Assoc. (1991) 199:1039-1042.
   PubMed Web of Science ®Google Scholar
• LALLEMAND F, FELT-BAEYENS O, BESSEGHIR K et al.: Cyclosproine A delivery to the eye: a pharmaceutical challenge. Eur. J. Pharm. Biopharm. (2003) 56:307-318.
   PubMed Web of Science ®Google Scholar
• SANSOM J, BARNETT KC, NEUMANN W et al.: Treatment of keratoconjunctivitis sicca in dogs with cyclosporine ophthalmic ointment: a European clinical field trial. Vet. Rec. (1995) 137:504-507.
   PubMed Web of Science ®Google Scholar
• CHEEKS L, KASWAN RL, GREEN K: Influence of vehicle and anterior chamber protein concentration on cyclosporine penetration through the isolated rabbit cornea. Curr. Eye Res. (1992) 11:641-649.
   PubMed Web of Science ®Google Scholar
• NEWTON C, GEBHARDT BM, KAUFMAN HE: Topically applied cyclosporine in azone prolongs corneal allograft survival. Invest. Ophthalmol. Vis. Sci. (1988) 29:208-215.
   Google Scholar
• TANG-LIU DD, RICHMAN JB, WEINKAM RJ et al.: Effects of four penetration enhancers on corneal permeability of drugs in vitro. J. Pharm. Sci. (1994) 83:85-90.
   PubMed Web of Science ®Google Scholar
• CALVO P, ALONSO MJ, VILA-JATO JL et al.: Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J. Pharm. Pharmacol. (1996) 48:1147-1152.
   PubMed Web of Science ®Google Scholar
• HICKOK S: Polyoxyethylene stearate. In: Wade A, Weller P (Eds), Handbook of Pharmaceutical Excipients. The Pharmaceutical Press, London, UK (1994):379-384.
   Google Scholar
• ABDULRAZIK M, TAMILVANAN S, KHOURY K et al.: Ocular delivery of cyclosporine A. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclosporin A. STP Pharma. Sci. (2001) 11:427-432.
   Google Scholar
• MILANI JK, PLEYER U, DUKES A et al.: Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology (1993) 100:890-896.
   PubMed Web of Science ®Google Scholar
• BOURGES JL, LALLEMAND F, AGLA E et al.: Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats. Mol. Vis. (2006) 12:1461-1466.
   PubMed Web of Science ®Google Scholar
• LALLEMAND F, FURRER P, FELT-BAEYENS O et al.: A novel water-soluble cyclosporine A prodrug: ocular tolerance and in vivo kinetics. Int. J. Pharm. (2005) 295:7-14.
   PubMed Web of Science ®Google Scholar
• REIDY JJ, GEBHARDT BM, KAUFMAN HE: The collagen shield. A new vehicle for delivery of cyclosporine A to the eye. Cornea (1990) 9:196-199.
   PubMed Web of Science ®Google Scholar
• HARPER CA, KHOOBEHI B, PEYMAN GA et al.: Bioavailability of microsphere-entrapped cyclosporine A in the cornea and aqueous of rabbits. Int. Ophthalmol. (1993) 17:337-340.
   PubMed Web of Science ®Google Scholar
• ALGHADYAN AA, PEYMAN GA, KHOOBEHI B et al.: Liposome-bound cyclosporine: aqueous and vitreous level after subconjunctival injection. Int. Ophthalmol. (1988) 12:101-104.
   PubMed Web of Science ®Google Scholar
• APEL A, OH C, CHIU R et al.: A subconjunctivalde gradable implant for cyclosporine delivery in corneal transplant therapy. Curr. Eye Res. (1995) 14:659-667.
   PubMed Web of Science ®Google Scholar
• ALGHADYAN AA, PEYMAN GA, KHOOBEHI B et al.: Liposome-bound cyclosporine: retinal toxicity after intravitreal injection. Int. Ophthalmol. (1988) 12:105-107.
   PubMed Web of Science ®Google Scholar
• XIE L, SHI W, WANG Z et al.: Prolongation of corneal allograft survival using cyclosporine in polylactide-co-glycolide polymer. Cornea (2001) 20:748-752.
   PubMed Web of Science ®Google Scholar